Emcure Pharmaceuticals Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹2,580Cr
- +22.8% YoY
- +4.5% QoQ
- Net profit
- ₹292Cr
- +35.8% YoY
- +19.7% QoQ
- Margin
- 21%
- +1 pp YoY
- +2 pp QoQ
What the Q1 FY27 call signalled
3 of 4 strong
The short version
Emcure expects low to mid-teen revenue growth for FY27 with positive movement quarter-over-quarter. Emcure expects low to mid-teen revenue growth in FY27, indicating steady top-line expansion.
From Emcure Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Emcure expects low to mid-teen revenue growth for FY27 with positive movement quarter-over-quarter.
- Domestic business growth is anticipated to improve from current levels, targeting to be in line with or faster than industry growth from Q2 onward.
- Organic domestic growth guided at 6%-8%, with acceleration expected in the second half of FY27.
- International business, especially Europe, Canada, and Rest of World markets, poised for solid growth supported by new launches, strong approval pipeline, and differentiated products.
- ARV and non-ARV segments in international markets expected to contribute roughly equally (~50:50) over the full year.
- R&D expenses will increase, maintaining around 4%-5% of revenues to support innovation and growth.
2 more points from Emcure Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Emcure Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company expects R&D expenses to increase, maintaining an outlook of 4% to 5% of revenue for FY27, indicating strategic investment in product development.
- They continue to focus on building differentiated capabilities in biologics, complex injectables, and novel delivery systems, particularly liposomal technology.
- Recent technology transfer initiatives include licensing a novel anti-HPV candidate from ICMR, part of women's health R&D pipeline.
- Entered a royalty-free licensing agreement with MSD to manufacture a generic oral HIV pill for low and lower-middle income countries, strengthening their ARV portfolio.
2 more points from Emcure Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Emcure Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Emcure is ramping up supplies across different countries, leading to an increase in the order book in line with supplies.
- The company sees good visibility on some order books, particularly in the ARV (antiretroviral) segment.
- The Rest of the World business growth is strongly supported by ARV and tender-based products with ongoing procurement cycles expected to pick up in coming quarters.
- Emcure expects continued momentum from new product launches and bolt-on acquisitions contributing to orderbook buildup.
Emcure Pharmaceuticals Ltd — Quarterly revenue & net profit
Emcure Pharmaceuticals Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 2,580 | 2,101 | +22.8% | 2,470 | +4.5% |
| Operating profit (EBITDA) | 532 | 417 | +27.6% | 480 | +10.8% |
| Operating margin | 21% | 20% | +1 pp | 19% | +2 pp |
| Profit before tax | 394 | 291 | +35.4% | 341 | +15.5% |
| Net profit (PAT) | 292 | 215 | +35.8% | 244 | +19.7% |
| EPS (₹) | 15.50 | 10.92 | +41.9% | 12.84 | +20.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.8K Cr, net profit ₹325 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Emcure Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Emcure Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Emcure Pharmaceuticals Ltd Q1 FY27 results?
Emcure expects low to mid-teen revenue growth for FY27 with positive movement quarter-over-quarter. Emcure expects low to mid-teen revenue growth in FY27, indicating steady top-line expansion.
What is Emcure Pharmaceuticals Ltd share price analysis?
Emcure Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 33.5 with a market cap of ₹34,539 Cr. Investors should review the full earnings analysis for detailed insights.
Is Emcure Pharmaceuticals Ltd planning capital expenditure?
The company expects R&D expenses to increase, maintaining an outlook of 4% to 5% of revenue for FY27, indicating strategic investment in product development.
Keep Emcure Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
